Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients

26. Juni 2022 aktualisiert von: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

A Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SHR-2002 Injection or in Combination With Other Anti-cancer Therapy in Advanced Malignant Tumors of Patients

The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of SHR-2002 injection monotherapy and in combination with other anti-cancer therapy for advanced malignant tumors of patients. To explore the reasonable dosage of SHR-2002 injection monotherapy and dosage regimen of combination therapy for advanced malignant tumors of patients.

Studienübersicht

Status

Anmeldung auf Einladung

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Voraussichtlich)

240

Phase

  • Phase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • China
    • Henan
      • Luoyang, Henan, China, 471003
        • Henan Science and Technology University First Affiliated Hospital
    • Hunan
      • Changsha, Hunan, China, 410006
        • Hunan Cancer Hospital
    • Shandong
      • Linyi, Shandong, China, 276002
        • Linyi Cancer Hospital
    • Shanghai
      • Shanghai, Shanghai, China, 200433
        • Shanghai Pulmonary Hospital
    • Sichuan
      • Chengdu, Sichuan, China, 410013
        • West China Hospital of Sichuan University

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 70 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Ability to understand and voluntarily agrees to participate by giving written informed consent for the study;
  2. Male or female aged ≥18 years and ≤70 years at the time of signing the ICF;
  3. Histopathologically or cytologically documented advanced or metastatic malignancies;
  4. An Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1;
  5. Life expectancy ≥12 weeks;
  6. Adequate organ functions as defined;
  7. Female and male patients of reproductive potential must agree to use highly effective contraception during the study treatment period and within 6 months after the last investigational drug administration; Female of childbearing potential must have a negative serum human chorionic gonadotropin (HCG) test within 7 days before the first dose of the investigational drugs and must not be breastfeeding.

Exclusion Criteria:

  1. Patients with known active central nervous system (CNS) metastases and/or carcinomatous meningitis;
  2. Patients with active brain metastasis (without medical control or with clinical symptoms), cancerous meningitis, spinal cord compression, or patients with a history of primary tumors of the central nervous system ;
  3. Patients with tumor-related pain that cannot be controlled as determined by the investigator;
  4. Uncontrollable third-space effusion, such as pleural effusion, pericardial effusion or peritoneal effusion;
  5. Systemic anti-tumor therapy within 28 days prior to the first dose of the study treatment;
  6. Surgical procedures requiring general anesthesia within 28 days prior to the first dose of the study treatment;
  7. Patients who have received >30 Gy of radical radiotherapy within 28 days before the first dose of study treatment;
  8. Unresolved CTCAE Grade >1 toxicity attributed to any prior anti-tumor therapy;
  9. Use of live attenuated vaccines within 28 days before the first dose of the study treatment;
  10. Patients who have received any systemic immunosuppressants within 14 days prior to the first dose of study treatment;
  11. Patients with interstitial pneumonitis or interstitial lung disease; past history of interstitial pneumonitis or interstitial lung disease requiring hormone therapy;
  12. History of autoimmune diseases;
  13. History of clinically significant bleeding symptom or bleeding tendency within 3 months before the first dose of study treatment;
  14. History of clinically significant cardiovascular or cerebrovascular diseases within 6 months prior to the first dose of study treatment;
  15. Evidence or history of arterial/venous thrombosis within 3 months before the first dose;
  16. Prior malignancy (other than current malignant tumor) within 5 ears before the first dose of study treatment;
  17. Known history of serious allergic reactions to the investigational product or its main ingredients;
  18. History of immunodeficiency;
  19. Presence of active hepatitis B or active hepatitis C;
  20. Severe infections within 4 weeks prior to the first study treatment;
  21. Evidence or history of active pulmonary tuberculosis within 1 year before study entry;
  22. any other conditions that are not suitable for participation in the study in the investigator's opinion.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Einzelne Gruppe
Arzneimittel: SHR-2002 injection、Camrelizumab for Injection, SHR-1316 injection, SHR-1701 injection
Firstly Dose Escalation and Dose Expansion of SHR-2002 injection monotherapy should be conducted. After RP2D and MTD of the SHR-2002 injection monotherapy were confirmed, Dose Escalation, Dose Expansion and Efficacy Expansion of SHR-2002 injection in combination with other anti-cancer treatment would be completed, including Camrelizumab for Injection, or SHR-1316 injection, or SHR-1701 injection.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Maximum tolerated dose
Zeitfenster: first dose of study medication up to 21 days
The Maximum tolerated dose of SHR-2002 injection monotherapy or in combination with Camrelizumab for Injection, or SHR-1316 injection, or SHR-1701 injection
first dose of study medication up to 21 days
Recommended phase II dose
Zeitfenster: first dose of study medication up to 21 days
The Recommended phase II dose of SHR-2002 injection monotherapy or in combination with Camrelizumab for Injection, or SHR-1316 injection, or SHR-1701 injection
first dose of study medication up to 21 days
Incidence and severity of adverse events (AEs)/serious adverse events (SAEs)
Zeitfenster: from signature completion of ICF to 90 days after the last dose or to the beginning of the new anti-cancer therapy, whichever came first, assessed up to 24 weeks
Incidence and severity of adverse events (AEs)/serious adverse events (SAEs) graded by Common Terminology Criteria for Adverse Events (CTCAE) v5.0
from signature completion of ICF to 90 days after the last dose or to the beginning of the new anti-cancer therapy, whichever came first, assessed up to 24 weeks

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Tmax
Zeitfenster: 0.5 hour before first dose to the 336 hours after first dose
PK parameters of single dose of SHR-2002 injection monotherapy
0.5 hour before first dose to the 336 hours after first dose
Cmax
Zeitfenster: 0.5 hour before first dose to the 336 hours after first dose
PK parameters of single dose of SHR-2002 injection monotherapy
0.5 hour before first dose to the 336 hours after first dose
AUC0-t
Zeitfenster: 0.5 hour before first dose to the 336 hours after first dose
PK parameters of single dose of SHR-2002 injection monotherapy
0.5 hour before first dose to the 336 hours after first dose
AUC0-∞
Zeitfenster: 0.5 hour before first dose to the 336 hours after first dose
PK parameters of single dose of SHR-2002 injection monotherapy
0.5 hour before first dose to the 336 hours after first dose
t1/2
Zeitfenster: 0.5 hour before first dose to the 336 hours after first dose
PK parameters of single dose of SHR-2002 injection monotherapy
0.5 hour before first dose to the 336 hours after first dose
CL
Zeitfenster: 0.5 hour before first dose to the 336 hours after first dose
PK parameters of single dose of SHR-2002 injection monotherapy
0.5 hour before first dose to the 336 hours after first dose
Vss
Zeitfenster: 0.5 hour before first dose to the 336 hours after first dose
PK parameters of single dose of SHR-2002 injection monotherapy
0.5 hour before first dose to the 336 hours after first dose
Cmax, ss
Zeitfenster: 0.5 hour before second dose to the 30 days after last dose
PK parameters of multiple doses of SHR-2002 monotherapy
0.5 hour before second dose to the 30 days after last dose
Ctrough, ss
Zeitfenster: 0.5 hour before second dose to the 30 days after last dose
PK parameters of multiple doses of SHR-2002 monotherapy
0.5 hour before second dose to the 30 days after last dose
Rac
Zeitfenster: 0.5 hour before second dose to the 30 days after last dose
PK parameters of multiple doses of SHR-2002 monotherapy
0.5 hour before second dose to the 30 days after last dose
RO
Zeitfenster: 0.5 hour before second dose to the 30 days after last dose
Receptor occupancy, PD indicators of SHR-2002 injection monotherapy
0.5 hour before second dose to the 30 days after last dose
Cytokine concentration
Zeitfenster: 0.5 hour before second dose to the 30 days after last dose
PD indicators of SHR-2002 injection monotherapy
0.5 hour before second dose to the 30 days after last dose
Ctrough, ss
Zeitfenster: 0.5 hour before second dose to the 90 days after last dose
PK parameters of SHR -2002, Camrelizumab for Injection, SHR-1316 injection and SHR-1701 injection during combination therapy period
0.5 hour before second dose to the 90 days after last dose
Rac
Zeitfenster: 0.5 hour before second dose to the 90 days after last dose
PK parameters of SHR -2002, Camrelizumab for Injection, SHR-1316 injection and SHR-1701 injection during combination therapy period
0.5 hour before second dose to the 90 days after last dose
ADA
Zeitfenster: 0.5 hour before second dose to the 90 days after last dose
Anti-drug antibody, Immunogenicity of SHR-2002 in monotherapy and combination therapy, Camrelizumab for Injection, SHR-1316 injection and SHR-1701 injection
0.5 hour before second dose to the 90 days after last dose
NAb
Zeitfenster: 0.5 hour before second dose to the 90 days after last dose
Immunogenicity of Camrelizumab for Injection, SHR-1316 injection and SHR-1701 injection
0.5 hour before second dose to the 90 days after last dose
ORR
Zeitfenster: from the date of the first dose to the date of disease progression evaluated based on RECIST v1.1 criteria, death, lost to follow-up, voluntary withdrawal, or initiation of other anti-tumor treatment, whichever occurs first, assessed up to 6 months]
Objective Response Rate, Efficacy endpoints of SHR-2002 injection monotherapy or in combination with Camrelizumab for Injection, or SHR-1316 injection, or SHR-1701 injection in treatment of patients with Advanced Malignant Tumors
from the date of the first dose to the date of disease progression evaluated based on RECIST v1.1 criteria, death, lost to follow-up, voluntary withdrawal, or initiation of other anti-tumor treatment, whichever occurs first, assessed up to 6 months]
DoR
Zeitfenster: from the date of the firstly documented tumor response to the date of the firstly documented disease progression or the date of death for any reason, assessed up to 6 months
Duration of response, Efficacy endpoints of SHR-2002 injection monotherapy or in combination with Camrelizumab for Injection, or SHR-1316 injection, or SHR-1701 injection in treatment of patients with Advanced Malignant Tumors
from the date of the firstly documented tumor response to the date of the firstly documented disease progression or the date of death for any reason, assessed up to 6 months
DCR
Zeitfenster: from the date of the first dose to the date of the firstly documented disease progression (evaluated based on RECIST v1.1 criteria) or the date of death for any reason, assessed up to 6 months
Disease control rate, Efficacy endpoints of SHR-2002 injection monotherapy or in combination with Camrelizumab for Injection, or SHR-1316 injection, or SHR-1701 injection in treatment of patients with Advanced Malignant Tumors
from the date of the first dose to the date of the firstly documented disease progression (evaluated based on RECIST v1.1 criteria) or the date of death for any reason, assessed up to 6 months
PFS
Zeitfenster: from the date of the first dose to the date of the firstly documented disease progression (evaluated based on RECIST v1.1 criteria) or the date of death for any reason, assessed up to 6 months
Progression-free survival, Efficacy endpoints of SHR-2002 injection monotherapy or in combination with Camrelizumab for Injection, or SHR-1316 injection, or SHR-1701 injection in treatment of patients with Advanced Malignant Tumors
from the date of the first dose to the date of the firstly documented disease progression (evaluated based on RECIST v1.1 criteria) or the date of death for any reason, assessed up to 6 months
OS
Zeitfenster: from the date of the first dose to the date of death for any reason，assessed up to 100 months
Overall survival, Efficacy endpoints of SHR-2002 injection monotherapy or in combination with Camrelizumab for Injection, or SHR-1316 injection, or SHR-1701 injection in treatment of patients with Advanced Malignant Tumors
from the date of the first dose to the date of death for any reason，assessed up to 100 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

22. Februar 2022

Primärer Abschluss (Voraussichtlich)

31. Januar 2023

Studienabschluss (Voraussichtlich)

30. Juni 2023

Studienanmeldedaten

Zuerst eingereicht

3. Januar 2022

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

17. Januar 2022

Zuerst gepostet (Tatsächlich)

20. Januar 2022

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

28. Juni 2022

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

26. Juni 2022

Zuletzt verifiziert

1. Juni 2022

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • SHR-2002-I-101

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

Unentschieden

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren